SGLT2 + GLP-1 Drugs: Mortality Impact in Diabetic Heart Failure
Analysis of SGLT2 and GLP-1 drug impact on mortality in diabetic heart failure patients finds both reduce death with potentially additive benefits when combined.
Quick Facts
What This Study Found
Analysis of SGLT2 and GLP-1 drug impact on mortality in diabetic heart failure patients finds both reduce death with potentially additive benefits when combined.
Key Numbers
CARDIAB cohort study. Patients with T2D and established ASCVD. Mortality reduction with SGLT2 inhibitors and GLP-1 RAs demonstrated.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Analysis of SGLT2 and GLP-1 drug impact on mortality in diabetic heart failure patients finds both r
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease.
- Published In:
- Cardiovascular diabetology, 24(1), 353 (2025)
- Authors:
- Arow, Ziad, Hornik-Lurie, Tzipi(2), Hilu, Ranin, Giladi, Ela, Arnson, Yoav, Vaknin-Assa, Hana, Assali, Abid, Pereg, David
- Database ID:
- RPEP-09984
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Analysis of SGLT2 and GLP-1 drug impact on mortality in diabetic heart failure patients finds both reduce death with potentially additive benefits when combined.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09984APA
Arow, Ziad; Hornik-Lurie, Tzipi; Hilu, Ranin; Giladi, Ela; Arnson, Yoav; Vaknin-Assa, Hana; Assali, Abid; Pereg, David. (2025). SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease.. Cardiovascular diabetology, 24(1), 353. https://doi.org/10.1186/s12933-025-02874-7
MLA
Arow, Ziad, et al. "SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease.." Cardiovascular diabetology, 2025. https://doi.org/10.1186/s12933-025-02874-7
RethinkPeptides
RethinkPeptides Research Database. "SGLT2 inhibitors and GLP-1 receptor agonists: impact on mort..." RPEP-09984. Retrieved from https://rethinkpeptides.com/research/arow-2025-sglt2-inhibitors-and-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.